Tag Archives: Lorenzo Biasio

Analysts Are Neutral on Top Healthcare Stocks: Pfizer (PFE), Axovant Gene Therapies (AXGT)

Analysts fell to the sidelines weighing in on Pfizer (PFE – Research Report) and Axovant Gene Therapies (AXGT – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Pfizer (PFE) In a

Credit Suisse Believes Merck & Company (NYSE: MRK) Won’t Stop Here

In a report issued on August 5, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $95. The company’s shares closed yesterday at $84.25, close to its

Mylan Inc (MYL) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Mylan Inc (MYL – Research Report) yesterday and set a price target of $34.50. The company’s shares closed yesterday at $20.90. According to TipRanks.com, Biasio is a 3-star analyst with

Thermo Fisher (TMO) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Thermo Fisher (TMO – Research Report) yesterday and set a price target of $310. The company’s shares closed yesterday at $277.68. According to TipRanks.com, Biasio is a 3-star analyst with

Illumina (ILMN) Receives a Buy from Credit Suisse

In a report released yesterday, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Illumina (ILMN – Research Report), with a price target of $340. The company’s shares closed yesterday at $299.38. According to TipRanks.com, Biasio is a 3-star

Pfizer (PFE) Receives a Hold from Credit Suisse

Credit Suisse analyst Lorenzo Biasio resumed coverage with a Hold rating on Pfizer (PFE – Research Report) on July 12 and set a price target of $47. The company’s shares closed on Friday at $42.40. According to TipRanks.com, Biasio is